نتایج جستجو برای: tp53 protein

تعداد نتایج: 1240012  

2001
Andrew R. Pettitt Paul D. Sherrington Grant Stewart John C. Cawley A. Malcolm R. Taylor Tatjana Stankovic

The well-established association between TP53 mutations and adverse clinical outcome in a range of human cancers reflects the importance of p53 protein in regulating tumor-cell growth and survival. Although it is theoretically possible for p53 dysfunction to arise through mechanisms that do not involve TP53 mutation, such a phenomenon has not previously been demonstrated in a sporadic tumor. He...

Journal: :Blood 2013
Yong Li Michael W Gordon Zijun Y Xu-Monette Carlo Visco Alexander Tzankov Dehui Zou Lugui Qiu Santiago Montes-Moreno Karen Dybkaer Attilio Orazi Youli Zu Govind Bhagat Kristy L Richards Eric D Hsi William W L Choi J Han van Krieken Qin Huang Weiyun Ai Maurilio Ponzoni Andrés J M Ferreri Jane N Winter Ronald S Go Miguel A Piris Michael B Møller Lin Wu Michael Wang Kenneth S Ramos L Jeffrey Medeiros Ken H Young

We identified multiple single nucleotide variants (SNVs) in the TP53 3' untranslated region (3'UTR) in tumor specimens from 244 patients with diffuse large B-cell lymphoma (DLBCL). Patients carrying a wild-type TP53 coding sequence (CDS) and 1 or more 3'UTR SNVs had a better 5-year survival rate than patients carrying a wild-type CDS and the reference 3'UTR, yet there is no statistically signif...

Journal: :Journal of medical genetics 2003
A-M Martin P A Kanetsky B Amirimani T A Colligon G Athanasiadis H A Shih M R Gerrero K Calzone T R Rebbeck B L Weber

Somatic mutations in TP53 are the most frequent events in human cancer and lead to inactivation of the gene, loss of tumour suppressor function, and in some cases generation of a dominant negative form of p53. Eleven exons make up the primary transcript of TP53, of which exons 2-11 encode the protein. Five conserved domains exist in exons 1, 4, 5, 7, and 8, which are considered essential for no...

2009
André S Khayat Adriana C Guimarães Danielle Q Calcagno Aline D Seabra Eleonidas M Lima Mariana F Leal Mário HG Faria Silvia HB Rabenhorst Paulo P Assumpção Samia Demachki Marília AC Smith Rommel R Burbano

BACKGROUND This study evaluates the existence of numerical alterations of chromosome 17 and TP53 gene deletion in gastric adenocarcinoma. The p53 protein expression was also evaluated, as well as, possible associations with clinicopathological characteristics. METHODS Dual-color fluorescence in situ hybridization and immunostaining were performed in twenty gastric cancer samples of individual...

Journal: :Blood 2001
A R Pettitt P D Sherrington G Stewart J C Cawley A M Taylor T Stankovic

The well-established association between TP53 mutations and adverse clinical outcome in a range of human cancers reflects the importance of p53 protein in regulating tumor-cell growth and survival. Although it is theoretically possible for p53 dysfunction to arise through mechanisms that do not involve TP53 mutation, such a phenomenon has not previously been demonstrated in a sporadic tumor. He...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Kexin Chen Zhibin Hu Li-E Wang Wei Zhang Adel K El-Naggar Erich M Sturgis Qingyi Wei

PURPOSE Tumor protein 53-binding protein 1 (TP53BP1) and TP53 interact during TP53-mediated transcriptional activation and during checkpoint activation in response to DNA damage. Because suboptimal repair of tobacco-induced DNA damage is associated with risk of squamous cell carcinoma of the head and neck (SCCHN), we hypothesized that potentially functional polymorphisms in TP53BP1 and TP53 may...

2010
Jenni K Peltonen Henni M Helppi Paavo Pääkkö Taina Turpeenniemi-Hujanen Kirsi H Vähäkangas

BACKGROUND Although TP53 mutations in human tumours generally have been extensively studied, the significance of p53 in the aetiology of head and neck cancers is still incompletely characterized. In recent years, considerable interest has been focused on mutant forms of p53, the abnormal protein product of TP53 alleles with missense mutation that often accumulate in cancer cells. METHODS We c...

2016
Silvia Darb-Esfahani Carsten Denkert Albrecht Stenzinger Christoph Salat Bruno Sinn Christian Schem Volker Endris Peter Klare Wolfgang Schmitt Jens-Uwe Blohmer Wilko Weichert Markus Möbs Hans Tesch Sherko Kümmel Peter Sinn Christian Jackisch Manfred Dietel Toralf Reimer Sherene Loi Michael Untch Gunter von Minckwitz Valentina Nekljudova Sibylle Loibl

BACKGROUND TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial. METHODS 450 pre-therapeutic, formalin-fixed, paraffin-embedded core biopsies from the phase II neoadjuvant GeparSixto trial that included HER2-positive and triple negative breast cancer (TNBC) were subjected to Sanger sequencing of exons 5-8 of the T...

Journal: :Cancer research 2010
Xueqin Chen Jing Gong Hao Zeng Ni Chen Rui Huang Ying Huang Ling Nie Miao Xu Juan Xia Fang Zhao Wentong Meng Qiao Zhou

The putative tumor suppressor miR145 is transcriptionally regulated by TP53 and is downregulated in many tumors; however, its role in prostate cancer is unknown. On the other hand, BCL2/adenovirus E1B 19-kDa interacting protein 3 (BNIP3) is overexpressed in various tumors, including prostate cancer, and may transcriptionally repress the apoptosis-inducing factor (AIF) gene. Although BNIP3 trans...

2016
Moshe Oren Perry Tal Varda Rotter

p53 tumor suppressor protein serves as a major barrier against cancer; consequently, mutations in the TP53 gene, encoding p53, are the most frequent single genetic alteration in human cancer, occurring in about half of all individual cancer cases [1]. Besides abrogating the tumor suppressive effects of the wild type (WT) p53 protein, many of the TP53 mutations endow the mutant p53 protein with ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید